Prospect: information for the user
Venlafaxine Retard MABO 75 mg prolonged-release hard capsules EFG
Read this prospect carefully before starting to take the medicine.
1. What is Venlafaxine Retard MABO and for what it is used
2. What you need to know before starting to takeVenlafaxine Retard MABO
3. How to take Venlafaxine Retard MABO
4. Possible adverse effects
5. Storage of Venlafaxine Retard MABO
6. Contents of the package and additional information
Venlafaxina Retard MABO contains the active ingredient venlafaxine.
Venlafaxina Retard MABO is an antidepressant that belongs to a group of medicines called serotonin and noradrenaline reuptake inhibitors (SNRIs). This group of medicines is used to treat depression and other conditions such as anxiety disorders. It is believed that people who are depressed and/or anxious have lower levels of serotonin and noradrenaline in the brain. The exact way in which antidepressants work is not fully understood, but they may help to increase the levels of serotonin and noradrenaline in the brain.
Venlafaxina Retard MABO is a treatment for adults with depression. It is also a treatment for adults with the following anxiety disorders: generalized anxiety disorder, social anxiety disorder (fear or avoidance of social situations), panic disorders (panic attacks). Treating depressive and anxiety disorders properly is important to help you feel better. If left untreated, your condition may not disappear or may worsen and become more difficult to treat.
Do not take Venlafaxina Retard MABO
Warnings and precautions
Consult your doctor or pharmacist before starting to take Venlafaxina Retard MABO
Venlafaxina Retard MABO may cause restlessness or difficulty sitting or staying still during the first few weeks of treatment. You should consult your doctor if this happens.
Some medicines in the group to which Venlafaxina Retard MABO belongs (called ISRS/IRSN) may cause sexual dysfunction symptoms (see section 4). In some cases, these symptoms persist after stopping treatment.
Do not drink alcohol during treatment with venlafaxine, as it may cause extreme fatigue and loss of consciousness. Taking it with certain medicines and/or alcohol may worsen symptoms of depression and other conditions, such as anxiety disorders.
Thoughts of suicide and worsening of depression or anxiety disorder
If you are depressed and/or have an anxiety disorder, you may sometimes have thoughts of harming yourself or
suiciding. This may be more likely to happen when you start taking antidepressants, as these medicines take time to work, usually two weeks but sometimes longer.
You may be more likely to experience this:
If you have thoughts of harming yourself or suiciding at any time, contact your doctor or go to the hospital emergency department immediately.
You may find it helpful to tell a close friend or family member that you are depressed or have an anxiety disorder and ask them to read this leaflet. You can also ask them to tell you if they think your depression or anxiety is getting worse, or if they are concerned about changes in your behavior.
Dry mouth
Dry mouth has been reported in 10% of patients treated with venlafaxine. This may increase the risk of tooth decay (caries). You should take good care of your dental hygiene.
Diabetes
Your blood glucose levels may be affected by Venlafaxina Retard MABO. Therefore, your diabetes medicines may need to be adjusted.
Venlafaxina Retard MABO should not normally be used in the treatment of children and adolescents under 18 years old. You should also know that in patients under 18 years old, there is a higher risk of adverse effects such as suicidal thoughts, suicidal behavior, and hostility (mainly aggression, confrontational behavior, and irritability) when taking this type of medicine. However,your doctorwho prescribes it may decide that it is the best option for the patient. If your doctor has prescribed this medicine to a patient under 18 years old, and you want to discuss this decision, please go back to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen in these patients under 18 years old who are taking Venlafaxina Retard MABO. Additionally, the long-term safety in relation to growth, maturation, and cognitive and behavioral development has not been demonstrated
Inform your doctor or pharmacist if you are using or have used recentlyor may need to use any other medicine.
Your doctor must decide if you can take Venlafaxina Retard MABO with other medicines.
Do not start or stop taking any medicine, including those available over the counter, natural remedies, and herbal products, without checking with your doctor or pharmacist.
Examples of these medicines include:
Medicines containing tramadol, fentanil, tapentadol, petidina, or pentazocina (used to treat severe pain)
The signs and symptoms of serotonin syndrome may include a combination of the following:
restlessness, hallucinations, loss of coordination, rapid heartbeat, increased body temperature, rapid changes in blood pressure, hyperactive reflexes, diarrhea, coma, nausea, vomiting.
In its most severe form, serotonin syndrome may resemble malignant neuroleptic syndrome (MNS). The signs and symptoms of MNS may include a combination of fever, rapid heartbeat, sweating, severe muscle rigidity, confusion, increased muscle enzymes (determined by blood test).
Inform your doctor immediately or go to the nearest hospital emergency department if you think you are experiencing serotonin syndrome.
Inform your doctor if you are taking medicines that may affect your heart rhythm.
Some examples of these medicines include:
The following medicines may interact with Venlafaxina Retard MABO and should be used with caution. It is especially important to mention to your doctor or pharmacist if you are taking medicines that contain:
Taking Venlafaxina Retard MABO with food, drinks, and alcohol
Venlafaxina Retard MABO should be taken with food (see section 3 “How to take Venlafaxina Retard MABO”).
Do not drink alcohol during treatment with venlafaxine. Taking it with alcohol may cause extreme fatigue and loss of consciousness, and worsen symptoms of depression and other conditions, such as anxiety disorders.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medicine. You should only take Venlafaxina Retard MABO after discussing the possible benefits and risks for the unborn baby with your doctor.
Make sure your midwife and/or doctor know that you are taking Venlafaxina MABO. When taken during pregnancy, similar medicines (ISRS) may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and turn blue. These symptoms usually start within the first 24 hours after the baby's birth. If this happens to your baby, contact your midwife and/or doctor immediately.
If you are taking this medicine during pregnancy, in addition to breathing problems, another symptom your baby may have when born is feeding problems. If your baby has these symptoms when born and you are concerned, contact your doctor and/or midwife who can advise you.
If you take Venlafaxina Retard MABO in the final stages of pregnancy, there may be a higher risk of heavy vaginal bleeding shortly after delivery, especially if you have a history of bleeding disorders. Your doctor or midwife should know that you are taking Venlafaxina Retard MABO so they can advise you.
Venlafaxina Retard MABO passes into breast milk. There is a risk of an effect on the baby. Therefore, you should discuss the case with your doctor and they will decide whether to stop breastfeeding or stop taking this medicine.
Driving and using machines
Do not drive or operate tools or machines until you know how this medicine affects you.
Follow the exact administration instructions for this medication. If in doubt, consult your doctor or pharmacist again.
The usual recommended initial dose for the treatment of depression, generalized anxiety disorder, and social anxiety disorder is 75 mg per day. Your doctor may gradually increase the dose and, if necessary, further up to a maximum of 375 mg per day for depression. If you are being treated for panic disorder, your doctor will start with a lower dose (37.5 mg) and then gradually increase the dose. The maximum dose for generalized anxiety disorder, social anxiety disorder, and panic disorder is 225 mg/day.
Take Venlafaxina Retard MABO approximately at the same time every day, either in the morning or at night. The capsules should be swallowed whole with liquids and should not be opened, crushed, chewed, or dissolved.
Venlafaxina Retard MABO should be taken with food.
If you have liver or kidney problems, talk to your doctor as your dose of this medication may need to be different.
Do not stop taking this medication without consulting your doctor (see section "If you interrupt treatment with Venlafaxina Retard MABO").
If you take more Venlafaxina Retard MABO than you should
In case of overdose or accidental ingestion, contact your doctor, pharmacist, or call the Toxicology Information Service, phone 91 562 04 20 indicating the medication and the amount ingested.
Overdose can put your life at risk, especially when taken with certain medications and/or alcohol (see Taking venlafaxine with other medications).
The symptoms of a possible overdose may include palpitations, changes in alertness (ranging from drowsiness to coma), blurred vision, seizures or attacks, and vomiting.
If you forgot to take Venlafaxina Retard MABO
If you have missed a dose, take it as soon as you remember. However, if it is already time for your next dose, skip the missed dose and take only one dose as usual. Do not take a double dose to compensate for the missed doses. Do not take more than the daily dose of Venlafaxina Retard MABO that you have been prescribed in a day.
If you interrupt treatment with Venlafaxina Retard MABO
Do not stop taking your treatment or reduce the dose without consulting your doctor, even if you feel better. If your doctor thinks you no longer need Venlafaxina Retard MABO, they may ask you to gradually reduce the dose before stopping treatment completely. It is known that adverse effects occur when people stop using this medication, especially when it is stopped suddenly or if the dose is reduced very quickly. Some patients may experience symptoms such as fatigue, dizziness, lack of stability, headache, insomnia, nightmares, dry mouth, loss of appetite, nausea, diarrhea, nervousness, agitation, confusion, ringing in the ears, tingling, or, in rare cases, electrical shock sensations, weakness, sweating, seizures, or flu-like symptoms.
Your doctor will advise you on how to gradually stop treatment with Venlafaxina Retard MABO. If you experience any of these or other symptoms that bother you, consult your doctor for advice.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
If any of the following effects occur, do not take more Venlafaxina Retard MABO.
Inform your doctor immediately, or go to the nearest hospital emergency room:
Rare (may affect up to 1 in 100 people)
Uncommon (may affect up to 1 in 1,000 people)
Other side effects that you should inform your doctor are (the frequency of these side effects are included in the list below “other side effects that may occur”):
Other side effects that may occur
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Rare (may affect up to 1 in 100 people)
Uncommon (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Unknown frequency
Venlafaxina Retard MABO may sometimes cause unwanted effects that you may not be aware of, such as increased blood pressure or abnormal heartbeat; mild changes in liver enzyme levels, sodium, or cholesterol levels. Your doctor may wish to perform occasional blood tests, particularly if you have been taking Venlafaxina Retard MABO for a long time.
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: http://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not use Venlafaxina Retard MABO after the expiration date that appears on the packaging, after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30°C.
Store in a dry place.
Medicines should not be disposed of through drains or in the trash. Deposit the containers and medicines you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. In this way, you will help protect the environment.
Composition of Venlafaxina Retard MABO 75 mg Hard-Shell Capsules with Prolonged Release
The active ingredient is venlafaxine. Each prolonged-release hard-shell capsule contains 75 mg of venlafaxine as venlafaxine hydrochloride.
The other components (excipients) are:
Caplet content: hypromellose, ammonio methacrylate copolymer (type B), sodium lauryl sulfate, magnesium stearate,
Covering: butylated basic methacrylate copolymer 12.5%,
Capsule coating: gelatin, titanium dioxide (E 171) and iron oxide red (E 172)
Printing ink: shellac lacquer, iron oxide black (E 172) and propylene glycol (E1520)
Appearance of the product and contents of the package
Prolonged-release hard-shell capsules of 75 mg in a beige opaque color, size 0, containing two round, biconvex, and film-coated tablets, marked with VEN on the cap and 75 on the body.
Package sizes for the 75 mg dose: 10, 14, 28, 30, 60, and 98 prolonged-release hard-shell capsules.
Only some package sizes may be commercially available.
Holder of the marketing authorization and responsible for manufacturing:
Holder of the marketing authorization
MABO-FARMA S.A.
Calle Rejas 2, 1st floor
28821. Coslada
Madrid
Responsible for manufacturing
Pharmathen International S.A.
Sapes Industrial Park
Block 5
69300 Rodopi
Greece
or
PHARMATHEN S.A.
6, Dervenakion Str
GR-15351 Pallini Attikis, Greece
or
ONE PHARMA INDUSTRIAL PHARMACEUTICAL COMPANY S.A.
60th km N.N.R. Athinon-Lamias
32009 Sximatari Voiotias, Greece
Last review date of this leaflet: April 2023
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.